echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Novartis® (Scucci Yumab) approved for psoriasis in children and adolescents in China

    Novartis® (Scucci Yumab) approved for psoriasis in children and adolescents in China

    • Last Update: 2021-08-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On August 17, Novartis Pharmaceuticals (China) announced that its innovative biological agent Keshan Ting® (Tecuzumab) has been approved by the National Medical Products Administration for the treatment of moderate to severe plaques that meet the indications for systemic therapy or phototherapy.


    Psoriasis is an immune-related chronic, recurrent, inflammatory, and systemic disease, with more than 125 million patients worldwide


    At present, Coshanting® has been approved for the treatment of psoriasis in children and adults, psoriasis of arthropathy, ankylosing spondylitis, and radiology-negative axial type in many countries and regions including the United States and European Union countries.


    In China, Coshanting® has been approved for the treatment of "adult patients with moderate to severe plaque psoriasis who meet the indications of systemic therapy or phototherapy" and "adult patients with ankylosing spondylitis with poor conventional therapy" Patients", and will be officially included in the National Medical Insurance Directory in 2020


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.